What 3 multibillion dollar biotechs still have to prove
Revolution Medicines' pancreatic cancer drug approval validated its technology and supported its $40B+ valuation. Summit Therapeutics, Abivax, and Viking Therapeutics, each with multibillion-dollar valuations, face key tests for their experimental drugs. Summit awaits FDA decision on ivonescimab for lung cancer; Abivax eyes 2026 FDA filing for obefazimod in ulcerative colitis; Viking develops obesity treatments to compete with market leaders.
How this was made
The 30-second read
Why it matters
Each company faces a binary catalyst (FDA decision, filing, or data readout) that can cause sharp price moves, while the capital raise for Viking adds dilution risk.
Market read
Regulatory milestones and financing events create near‑term trading opportunities across the biotech sector.
What to watch
Competition from larger pharma in obesity and ulcerative colitis could limit market share even if approvals are secured.
Background
The article surveys three high‑valuation biotech companies—Summit Therapeutics, Abivax, and Viking Therapeutics—highlighting their pending regulatory milestones and recent financing activities.
Ticker impact
Summit Therapeutics awaits FDA decision for ivonescimab with an action date set for Nov. 14, and recent trial readouts were positive but not yet statistically significant.
likely upside if FDA approves, downside risk if decision is delayed or negative
The upcoming regulatory deadline and mixed trial data create a binary catalyst that can move the share price sharply.
Viking Therapeutics raised over $500 million via a common stock and convertible senior notes offering in September to fund its obesity pipeline.
short‑term pressure from dilution, long‑term upside if obesity data are positive
Large fundraising is a material event for a $3 billion‑cap biotech, creating both risk and opportunity.
Market effects
Positive trial data and regulatory milestones could lift the broader biotech sector, especially oncology and obesity therapeutics.
US biotech investors may see increased volatility; European investors watch Abivax's progress.
These developments affect global biotech pipelines and could influence cross‑border capital flows.
Counterpoint
If FDA delays are common, the upside may be overstated; investors should price in a higher probability of setbacks.
Key entities
- companySummit Therapeutics
US biotech developing ivonescimab, a PD‑1/VEGF bispecific for lung cancer.
- companyAbivax
France‑based biotech pursuing obefazimod for ulcerative colitis.
- companyViking Therapeutics
US obesity‑focused biotech raising $500 M to fund its pipeline.
